After more than a decade of failed drug development efforts, osteoarthritis remains one of biopharma’s most stubborn challenges. Despite affecting more than 600 million people worldwide, no therapy approved in Europe or the United States has yet been shown to slow or modify disease progression. Against that backdrop, 4Moving Biotech (4MB) is betting that a familiar drug class, GLP-1 receptor agonists, can succeed where others have fallen short.
4Moving Biotech raises €12m to prove whether GLP-1 can crack osteoarthritis
Latest NewsAfter more than a decade of failed drug development efforts, osteoarthritis remains one of biopharma’s most stubborn challenges. Despite affecting more than 600 million people worldwide, no therapy approved in Europe or the United States has yet been shown to slow or modify disease progression. Against that backdrop, 4Moving Biotech (4MB) is betting that a familiar drug class, GLP-1 receptor agonists, can succeed where others have fallen short.
Bayer: At last, success with coagulation factor XIa in phase 3 stroke trial
Latest NewsBayer can report a success in stroke treatment, even though an earlier study with the same compound had been discontinued due to limited benefit. The approach of inhibiting factor XIa represents a first-in-class example from Leverkusen. Whether the data will be sufficient for regulatory approval remains to be seen.
Dublin-based Aerska secures $39M Series A to push RNA medicines into the brain
Latest NewsAerska, a biotechnology company focused on RNA medicines for brain diseases, has raised €32 million in a Series A financing to advance its lead technology toward clinical development. The round was co-led by EQT Life Sciences through its LSP Dementia Fund, alongside age1, and brings the company’s total funding to €50 million since its seed round in October 2025.
U.K. life sciences infrastructure gets a boost as London and Cambridge expand
Latest NewsTwo of the U.K.’s largest life sciences real-estate projects have moved forward within days of each other, with major expansion plans unveiled in London and Cambridge as both regions look to add new laboratory and research capacity.
SciVario® twin: One Controller for All Your Needs
ProductsEfficiency and flexibility are key factors to stay competitive in the bioprocess field. This is the idea behind SciVario twin, a control unit for small- and bench-scale bioprocess development and optimisation.
BioArctic is cashing in on Eisai and Biogen growing sales in Alzheimer’s disease
Latest NewsStockholm-based BioArctic is receiving SEK 127 million (about €11.9 million at today’s exchange rate) in royalties from the Alzheimer’s disease therapy Leqembi (lecanemab).
Agomab goes public on Nasdaq as biotech IPOs top $1bn in a single week
Latest NewsJust three weeks after announcing its plans for a U.S. listing, Belgium-based Agomab has gone public on Nasdaq after pricing its IPO at $16 per share, aiming to bring in about $200 million in gross proceeds with its stock now trading under the ticker AGMB.
Novartis celebrates strong profits, while the CEO enjoys record pay triggering discussion
Latest NewsNovartis increased its annual profit in 2025 to USD 17.4 billion and raised its dividend. Towards the end of the year, however, growth weakened markedly, weighed down by copycat products. The group has therefore issued a cautious outlook for 2026. The CEO’s high, bonus-driven remuneration has sparked debate.
Leyden Labs reports first human data for intranasal flu prevention antibody
Latest NewsLeyden Labs has released new early-stage data on its intranasal antibody program for influenza prevention, adding phase 1 human safety results to previously disclosed animal studies.
Pentixapharm: positive Phase II data on Pentixafor PET diagnostics pave way for radiotherapeutics
Latest NewsPentixapharm Holding AG published new clinical Phase II data on its radiodiagnostic agent [68Ga]Ga-Pentixafor in early February. As the Berlin-based company reported, the results published in the Journal of Nuclear Medicine confirm the potential of Pentixafor PET/CT as a non-invasive alternative to adrenal venous sampling (AVS) for the subtyping of primary aldosteronism.